Third Arc Bio
PrivateLast Round
Series A
Extension
Feb 4, 2026
Total Funding Raised
$249M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Third Arc Bio is a biotechnology company that develops multifunctional antibodies designed to precisely activate or inhibit T cells for the treatment of solid tumors, inflammation, and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Third Arc Bio Comparables
Compare Third Arc Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Voro Therapeutics | 82% | |
| EvolveImmune Therapeutics | 81% | |
| Xilio Therapeutics | 79% |
Third Arc Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 4, 2026 | ||||
| Series A | Jul 23, 2024 |
Key People
Founding team and executive leadership
Third Arc Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A Extension |
| Janus Henderson Group | Series A |
| Aberdeen Group plc | Series A Extension, Series A |
| Omega Funds | Series A, Seed, Series A Extension |
| Hillhouse Investment | Series A Extension, Series A |
| abrdn Inc. | Series A, Series A Extension |
| Cormorant Asset Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 73% MoM, reaching 6.3K.
- Jul 25, 2026
Monthly visitors grew 100% MoM, reaching 3.7K.
Third Arc Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Third Arc Bio's valuation, stock price, and market status.
Is Third Arc Bio a public or private company?
Third Arc Bio is a private company.
What is the current stock price of Third Arc Bio?
Third Arc Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Third Arc Bio worth (valuation)?
Valuation information for Third Arc Bio is not publicly available.
Can I buy Third Arc Bio stock?
Third Arc Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Third Arc Bio's last funding round?
Third Arc Bio's most recent funding round was Series A Extension on February 4, 2026.
Who are the main investors in Third Arc Bio?
Key investors in Third Arc Bio include Andreessen Horowitz, Omega Funds, Hillhouse Investment, Vida Ventures, Cormorant Asset Management.
Will Third Arc Bio IPO soon?
No public IPO plans have been announced for Third Arc Bio.
How can I track Third Arc Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Third Arc Bio's secondary market activity and sign up for updates.